Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China

Background: The 2015 European pulmonary hypertension (PH) guidelines recommend a risk stratification strategy for pulmonary arterial hypertension (PAH). We aimed to investigate the validation and potential prognostic information in Chinese patients.Methods: The risk assessment variables proposed by...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Su-Gang Gong, Wen-Hui Wu, Chao Li, Qin-Hua Zhao, Rong Jiang, Ci-Jun Luo, Hong-Ling Qiu, Jin-Ming Liu, Lan Wang, Rui Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	pulmonary arterial hypertension idiopathic pulmonary arterial hypertension risk assessment guideline prognosis Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/fad0d632f83042c09e218ee1d006ae2c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fad0d632f83042c09e218ee1d006ae2c
record_format	dspace
spelling	oai:doaj.org-article:fad0d632f83042c09e218ee1d006ae2c2021-11-22T04:57:43ZValidity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China2297-055X10.3389/fcvm.2021.745578https://doaj.org/article/fad0d632f83042c09e218ee1d006ae2c2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.745578/fullhttps://doaj.org/toc/2297-055XBackground: The 2015 European pulmonary hypertension (PH) guidelines recommend a risk stratification strategy for pulmonary arterial hypertension (PAH). We aimed to investigate the validation and potential prognostic information in Chinese patients.Methods: The risk assessment variables proposed by the PH guidelines were performed by using the WHO function class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right arterial pressure, cardiac index, mixed venous saturation, right atrium area, pericardial effusion, peak oxygen consumption, and ventilatory equivalents for carbon dioxide. An abbreviated version also was applied.Results: A total of 392 patients with idiopathic PAH (IPAH) were enrolled between 2009 and 2018. After a median interval of 13 months, re-evaluation assessments were available for 386 subjects. The PAH guidelines risk tool may effectively discriminate three risk groups and mortality (p < 0.001) both at the baseline and re-evaluation. Meanwhile, its simplified risk version was valid for baseline and accurately predicted the risk of death in all the risk groups (p < 0.001). At the time of re-evaluation, the percentage of low-risk group has an increase, but a greater proportion achieved the high-risk group and a lesser proportion maintained in the intermediate-risk group.Conclusion: The 2015 European PH guidelines and its simplified version risk stratification assessment present an effective discrimination of different risk groups and accurate mortality estimates in Chinese patients with IPAH. Changes of risk proportion at re-evaluation implicated that natural treatment decisions may not be consistently with goal-oriented treatment strategy.Su-Gang GongWen-Hui WuChao LiQin-Hua ZhaoRong JiangCi-Jun LuoHong-Ling QiuJin-Ming LiuLan WangRui ZhangFrontiers Media S.A.articlepulmonary arterial hypertensionidiopathic pulmonary arterial hypertensionrisk assessmentguidelineprognosisDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pulmonary arterial hypertension idiopathic pulmonary arterial hypertension risk assessment guideline prognosis Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	pulmonary arterial hypertension idiopathic pulmonary arterial hypertension risk assessment guideline prognosis Diseases of the circulatory (Cardiovascular) system RC666-701 Su-Gang Gong Wen-Hui Wu Chao Li Qin-Hua Zhao Rong Jiang Ci-Jun Luo Hong-Ling Qiu Jin-Ming Liu Lan Wang Rui Zhang Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
description	Background: The 2015 European pulmonary hypertension (PH) guidelines recommend a risk stratification strategy for pulmonary arterial hypertension (PAH). We aimed to investigate the validation and potential prognostic information in Chinese patients.Methods: The risk assessment variables proposed by the PH guidelines were performed by using the WHO function class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right arterial pressure, cardiac index, mixed venous saturation, right atrium area, pericardial effusion, peak oxygen consumption, and ventilatory equivalents for carbon dioxide. An abbreviated version also was applied.Results: A total of 392 patients with idiopathic PAH (IPAH) were enrolled between 2009 and 2018. After a median interval of 13 months, re-evaluation assessments were available for 386 subjects. The PAH guidelines risk tool may effectively discriminate three risk groups and mortality (p < 0.001) both at the baseline and re-evaluation. Meanwhile, its simplified risk version was valid for baseline and accurately predicted the risk of death in all the risk groups (p < 0.001). At the time of re-evaluation, the percentage of low-risk group has an increase, but a greater proportion achieved the high-risk group and a lesser proportion maintained in the intermediate-risk group.Conclusion: The 2015 European PH guidelines and its simplified version risk stratification assessment present an effective discrimination of different risk groups and accurate mortality estimates in Chinese patients with IPAH. Changes of risk proportion at re-evaluation implicated that natural treatment decisions may not be consistently with goal-oriented treatment strategy.
format	article
author	Su-Gang Gong Wen-Hui Wu Chao Li Qin-Hua Zhao Rong Jiang Ci-Jun Luo Hong-Ling Qiu Jin-Ming Liu Lan Wang Rui Zhang
author_facet	Su-Gang Gong Wen-Hui Wu Chao Li Qin-Hua Zhao Rong Jiang Ci-Jun Luo Hong-Ling Qiu Jin-Ming Liu Lan Wang Rui Zhang
author_sort	Su-Gang Gong
title	Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
title_short	Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
title_full	Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
title_fullStr	Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
title_full_unstemmed	Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China
title_sort	validity of the esc risk assessment in idiopathic pulmonary arterial hypertension in china
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/fad0d632f83042c09e218ee1d006ae2c
work_keys_str_mv	AT suganggong validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT wenhuiwu validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT chaoli validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT qinhuazhao validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT rongjiang validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT cijunluo validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT honglingqiu validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT jinmingliu validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT lanwang validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina AT ruizhang validityoftheescriskassessmentinidiopathicpulmonaryarterialhypertensioninchina
_version_	1718418199140106240

Validity of the ESC Risk Assessment in Idiopathic Pulmonary Arterial Hypertension in China

Ejemplares similares